MorphoSys AG Receives Two Phase 2 Milestone Payments From Janssen Biotech Inc.
Published: Sep 17, 2013
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today it received clinical milestone payments from Janssen Biotech, Inc. ("Janssen") following the initiation of two clinical trials. One trial initiated in asthmatic patients is studying the HuCAL antibody CNTO 3157 and a second trial initiated in patients with active rheumatoid arthritis is studying the HuCAL antibody CNTO 6785. Further financial details were not disclosed.
Help employers find you! Check out all the jobs and post your resume.